Cathay Capital, a global investment firm, agreed to invest in TransCure bioServices, a biotechnology company. Financial terms were not disclosed. “We are very happy to work with Patrick Nef, Sébastien Tabruyn and the management team to support them in the company’s ambitious project. TransCure bioServices benefits from unique scientific expertise on humanized mouse models across a variety of therapeutic areas, in a highly specialized rapidly growing preclinical market. We are delighted that they have chosen Cathay as partners and look forward to accompanying their growth by leveraging our global platform, ecosystem, and long-standing commitment to the healthcare industry.” Fabien Wesse, Cathay Capital Managing Partner.